Novo Nordisk's Oral Wegovy Racks Up 3 Million Prescriptions as $25 Million Ransomware Threat Looms
Published on 06/18/2026 at 14:15 | Redaktion boerse-global.de
Novo Nordisk finds itself caught between a commercial breakthrough and a cybersecurity crisis. The Danish drugmaker's new oral formulation of Wegovy has generated more than three million prescriptions in the United States since its January launch, a dramatic expansion of the addressable market. But that achievement now competes for investor attention with a ransomware attack that has put 1.3 terabytes of sensitive data at risk.
Shares in the company traded at €37.97, a decline of roughly 41 percent over the past twelve months. That puts the equity far below its 52-week high of €65.20, though the stock has clawed back about 24 percent from the March trough of €30.25. The 50-day moving average of €36.86 has been reclaimed, and the relative strength index of 53 indicates neither overbought nor oversold conditions — a tentative technical stabilization after a brutal correction.
The oral Wegovy pill represents the most tangible catalyst for a turnaround. More than 80 percent of the three million US patients who have filled prescriptions since January 5 are first-time GLP-1 users who had never tried injectable treatments. The needle-free option is pulling in a new cohort of patients, rather than simply cannibalising the existing injection franchise. On June 11, the UK's Medicines and Healthcare products Regulatory Agency approved a 25-milligram semaglutide tablet, backing its decision with data from the OASIS-4 study showing a 13.6 percent weight loss over 64 weeks compared with 2.4 percent in the placebo arm. CEO Mike Doustdar has also signalled plans to file for Chinese approval within months, an effort to beat Eli Lilly's own oral candidate to the world's second-largest pharmaceutical market.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
All of this commercial momentum now sits under the shadow of a cyber extortion. The ransomware group FulcrumSec claims to have exfiltrated 1.3 terabytes of data, including source code, clinical trial records, employee information and artificial intelligence models. The group is demanding $25 million and threatening to release the material. Novo Nordisk discovered the breach on June 11 and has confirmed that pseudonymised study data and physician details were compromised, though it stressed that operations and product shipments remain unaffected. Analysts suspect the attackers gained access via exposed credentials in development environments.
The company has not let the cyber incident slow its strategic expansion. A partnership with Boston-based Vivtex, worth up to $2.1 billion, will leverage the biotech's GI-ORIS platform to improve oral delivery of biologics — a critical battleground against Lilly. Another collaboration with Replicate Bioscience, carrying potential milestone payments of $550 million, targets self-replicating RNA therapies for metabolic diseases. On the manufacturing front, Novo Nordisk is investing roughly €432 million in its Athlone facility in Ireland, with completion slated for 2028, a move to secure production capacity for the coming wave of oral therapies.
The stock's steep decline over the past year reflected a confluence of pressures: US drug-pricing interventions, Medicare negotiations, and intensifying competition in the obesity market. The primary source argues that the worst of those headwinds are now fully priced into the valuation, and the market is gradually shifting from a narrative of infinite growth to one of sustainable volume expansion. The oral pill's ability to attract GLP-1-naive patients supports that thesis by enlarging the total addressable market.
Yet the next few weeks could hinge on how the ransomware saga unfolds. A successful data leak could tarnish Novo Nordisk's reputation and invite regulatory scrutiny, potentially weighing on the shares as the company tries to project confidence. For now, the strong script count, the UK approval and the China ambitions provide a solid foundation — but the cyber risk adds a layer of uncertainty that investors will watch closely. How management handles the communication of the breach, and whether FulcrumSec carries out its threat, may determine whether the stock can build on its recent technical recovery or stalls again.
Ad
Novo Nordisk Stock: New Analysis - 18 June
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
